The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Gene therapy delays & the implications of Covid-19 serology

By Meghana Keshavan

The READOUT
The Readout

Doing business in a pandemic & the ATM’s still open for small biotechs

By Damian Garde

The READOUT
The Readout

Allakos keeps a promise & Celgene’s legacy gets tested

By Damian Garde

The READOUT
The Readout

A new take on cell therapy & how close is a coronavirus drug?

By Damian Garde

The READOUT
The Readout

A treasure trove for the health industry & how scientific publishing is changing

By Meghana Keshavan

The READOUT
The Readout

Trump’s Covid-19 comments & Apple Watch’s remote trial

By Meghana Keshavan

The READOUT
The Readout

WHO launches global clinical trial & a hopeful take on remdesivir

By Meghana Keshavan

The READOUT
The Readout

Sage’s setback & pandemic problems for biotech

By Damian Garde

The READOUT
The Readout

How much coronavirus data does Moderna need? Plus: CureVac has an interesting month

By Damian Garde

The READOUT
The Readout

A closer look at remdesivir & non-coronavirus research slows

By Meghana Keshavan

The READOUT
The Readout

Voices from the coronavirus outbreak & deaths after stool transplants

By Damian Garde

The READOUT
The Readout

Moderna’s coronavirus gamble & a scrappy startup steps up

By Damian Garde

The READOUT
The Readout

A unicorn falters & PhRMA closes its doors to coronavirus

By Damian Garde

The READOUT
The Readout

A new coronavirus accelerator & whither Intarcia’s FDA decision?

By Kate Sheridan

The READOUT
The Readout

In silico vaccines for coronavirus, & the AHA backpedals on Bayer

By Meghana Keshavan

The READOUT
The Readout

Former Gates CEO on coronavirus & a gene therapy bonanza

By Damian Garde

The READOUT
The Readout

PhRMA’s promise on coronavirus pricing & a CRISPR milestone

By Damian Garde

The READOUT
The Readout

A contrarian take on R&D costs and thrice-delayed clinical data

By Damian Garde

The READOUT
The Readout

Biotech’s White House summit & Gilead’s latest deal

By Damian Garde

The READOUT
The Readout

Coronavirus cancellations & startup performance

By Damian Garde

The READOUT
The Readout

‘The Readout LOUD’ turns 100 & an AI moment of truth

By Meghana Keshavan

The READOUT
The Readout

The $100 genome & scrutinizing Allakos trials

By Meghana Keshavan

The READOUT
The Readout

ICER changes its mind & FDA rule triggered price hikes

By Meghana Keshavan

The READOUT
The Readout

Sanofi mixes up the ingredients market & an ocular warning for Novartis

By Damian Garde

The READOUT
The Readout

A Waksal comeback story & searching for Alzheimer’s hope

By Meghana Keshavan

The READOUT
The Readout

Startup overcrowding & the first gene therapy for hemophilia

By Damian Garde

The Readout

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

By Damian Garde

The READOUT
The Readout

Drugging lobster blood & a pivotal Incyte trial

By Meghana Keshavan

The READOUT
The Readout

Wall Street bails on Amarin & the latest twist in personal genomics

By Damian Garde

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy